Lesen Sie hier weiter... |  Drucken |  PDF

Ähnliche Artikel

• XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
• XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events in Small Vessel Patients Out to One Year
• Drug-Eluting Coronary Stents Utilizing Isotechnika's Lead Drug Receive Approval to Enter Clinical Trials
• Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First'Real World, All Comers' Clinical Study
• Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines
• Resverlogix's Lead Drug Featured in Key Scientific Publication
• Der mit Perikard ummantelte Over-and-Under(R)-Stent wird jetzt in England benutzt und lässt sich hervorragend einsetzen
• FDA erteilt Zulassung für Taclonex Scalp(R), eine einmal tägliche Behandlung mittelschwerer bis schwerer Psoriasis der Kopfhaut
• European Medicines Agency (EMEA) Approves Relistor(TM) The First-in-Class Treatment of Opioid-Induced Constipation (OIC) in Advanced-Illness Patients
• ProteoTechs Exebryl-1(R) zur Behandlung der Alzheimer-Krankheit tritt in die Phase der klinischen Studien am Menschen ein

Presseportal: Abbott Laboratories - Abbott stellt neue Ergebnisse zu ...

Abbott Laboratories: Abbott Park, Illinois (ots/PRNewswire) - - Zu den Highlights geh 23:01 FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent.03.06.

Neue_produkte News | PresseEcho.de

FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent.Abbott Park, Illinois (ots/PRNewswire) - - XIENCE V, Only Drug Eluting Stent to

ots.at: das APA-OTS-Portal für multimediale Presseaussendungen

FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent = 02.07.2008 / 23:03 XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events

Abbott Laboratories Pressemitteilungen News - PresseEcho.de

FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events

Presseportal.de - Abbott Laboratories

FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent XIENCE(TM) V Drug Eluting Stent from Abbott Reduces Major Adverse Cardiac Events